Porton Advanced Solutions

Porton Advanced Solutions is a Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) specialising in the development and manufacturing of Advanced Therapy Medicinal Products (ATMPs). Established in 2018 and headquartered in Suzhou, China, Porton Advanced is a subsidiary of Porton Pharma Solutions Ltd. The company offers comprehensive services spanning the entire lifecycle of ATMPs, from early-stage research through to commercial production.

Key Products and Services

Porton Advanced provides a wide array of services tailored to the needs of biotechnology and pharmaceutical companies, academic institutions, and hospitals. These services include:

Cell and Gene Therapy Platforms: Development and manufacturing of autologous and allogeneic cell therapies, including CAR-T, TCR-T, CAR-NK, stem cells, and exosomes.

Viral Vector Production: Manufacturing of lentiviral vectors, adeno-associated viruses (AAVs), and adenoviral vectors for gene delivery applications.

Nucleic Acid Therapies: Production of mRNA, circRNA, and plasmid DNA for therapeutic use.

Analytical and Testing Services: Comprehensive testing and quality control services, including method development, qualification, and validation for various therapeutic products.

Process and Analytical Development: Support in process development and analytical method development to optimise production and ensure product quality.

cGMP Manufacturing: Good Manufacturing Practice-compliant manufacturing services across plasmids, cell engineering, virotherapy, and mRNA-based therapeutic platforms.

Integrated IND-enabling Study Services: Provision of services to support Investigational New Drug applications, including preclinical and clinical study support.

Technology Licensing: Offering proprietary technologies and platforms for client licensing to enhance development capabilities.

Facilities and Capabilities

Porton Advanced operates a state-of-the-art, 215,000 square foot GMP-compliant facility equipped with multiple production lines for viral vectors and cell therapies. The company's infrastructure supports the manufacturing needs of various therapeutic modalities, ensuring scalability and compliance with international quality standards.

Conclusion

As a subsidiary of Porton Pharma Solutions, Porton Advanced leverages its parent company's global recognition and expertise in process innovation, supply chain performance, and compliance with global quality and environmental, health, and safety standards. Porton Advanced is committed to accelerating the development and manufacture of advanced therapies, aiming to deliver life-changing benefits to patients worldwide.